Immunomedics company information, Employees & Contact Information

Gilead Sciences to Acquire Immunomedics Business Wire

Immunomedics Receives Complete Response Letter From FDA for GlobeNewswire

FDA Approves First Antibody-Drug Conjugate for Metastatic Triple-Negative Breast Cancer Medical Professionals Reference

Gilead's Immunomedics floats $4M to put ASCO data fiasco to bed Fierce Pharma

Immunomedics Awarded Three US Patents Covering Its Cancer Therapeutic Product Candidates and Technologies NBC News

-Gilead bolsters cancer portfolio with $21 bln acquisition of Immunomedics Reuters

Gilead Reaches Deal to Buy Immunomedics for $21 Billion The Wall Street Journal

Immunomedics halts late-stage clinical trial, confirming drug benefit for aggressive type of breast cancer statnews.com

Gilead closing Immunomedics plant in NJ operations overhaul BioProcess International

Immunomedics shares double after Gilead agrees to buy the cancer drugmaker in $21 billion deal CNBC

Gilead to acquire Immunomedics for $21 billion CNN

Immunomedics To Present At Stifel Nicolaus Conference; Webcast At 10:55 AM ET RTTNews

Immunomedics Announces FDA Acceptance for Filing of GlobeNewswire

Did Gilead overpay for Immunomedics? Trodelvy answered that $21B-dollar question at ESMO: analyst Fierce Pharma

Immunomedics Announces Promotion Agreement With Janssen for Erdafitinib in the U.S. GlobeNewswire

Gilead splashes out $21B for Immmunomedics, keeping the pedal on new target weeks after AZ-Daiichi deal Fierce Pharma

Immunomedics to Host Investor Event and Webcast on September 28, 2019 During ESMO Congress GlobeNewswire

Gilead Sciences will lay off 114 staffers based out of former Immunomedics headquarters Fierce Pharma

Immunomedics and Everest Medicines Announce Exclusive GlobeNewswire

IMMUNOMEDICS ANNOUNCES EXECUTIVE LEADERSHIP CHANGES AND THE GlobeNewswire

Gilead to buy cancer drugmaker Immunomedics for $21B BioPharma Dive

Immunomedics wows ESMO with breast cancer data reveal pharmaphorum

Immunomedics could be facing longer lead drug delay as CEO quits Fierce Biotech

Immunomedics nabs J&J veteran for CMO as it presses on with ADC redo Fierce Biotech

Immunomedics raises $459M as Trodelvy breast cancer launch kicks off amid COVID-19 Fierce Pharma

Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal Citeline News & Insights

New Candidate Antibody-Drug Conjugate Gains Broad Patent Coverage NBC News

Immunomedics finally wins its blockbuster FDA nod for Trodelvy in triple-negative breast cancer Fierce Pharma

FDA uncovers data manipulation at Immunomedics plant making cancer drug Fierce Pharma

Gilead Moves Deeper into Oncology with $21 Billion Acquisition of Immunomedics BioSpace

Iannone walks out on troubled Immunomedics a year after taking CMO job Fierce Biotech

Troubled Immunomedics now hit with CRL for breast cancer drug candidate Fierce Pharma

Inside Gilead’s $21 billion purchase of Immunomedics: Lamb chops, steak, and a chance for transformation statnews.com

Activist investor moves to block Immunomedics deal BioPharma Dive

Former Immunomedics CFO pleads guilty to securities fraud over Trodelvy tip Fierce Biotech

Immunomedics' new CEO hits COVID-19 exit, takes $1M on his way out Fierce Pharma

Immunomedics' deal mastermind in line for $2.35B payout after Gilead buy—despite the lack of a bidding war Fierce Pharma

VenBio slams timing, terms of Immunomedics’ $2B deal Fierce Biotech

After months of searching, Immunomedics lines up Celgene vet Pehl as its new CEO Fierce Biotech

Jazz Pharma nabs Immunomedics' Iannone as R&D chief Fierce Biotech

AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy Fierce Biotech

Seattle kills off $2B Immunomedics deal as biotech’s CEO and founder axed Fierce Biotech

The top 10 takeover targets in biopharma Fierce Biotech

Why Immunomedics Shares Crashed 13.5% Today The Motley Fool

UCB Terminates Epratuzumab Collaboration with Immunomedics Genetic Engineering and Biotechnology News

Ex-girlfriend of former Immunomedics CFO Usama Malik pleads guilty to fraud Fierce Biotech

Gilead sues former CFO of Immunomedics to claw back $4 million The Business Journals

Immunomedics Sale Hinges on Proxy Battle Over Fate of Controversial Founder TheStreet

Gilead to buy cancer drugmaker Immunomedics for US$21 billion The Straits Times